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Abstract
Nuclear receptors (NR) are a major transcription factor family whose members selectively bind 
small molecule lipophilic ligands and transduce those signals into specific changes in gene 
programs. For over two decades, structural biology efforts were directed exclusively on the 
individual ligand binding domains (LBDs) or DNA binding domains (DBDs) of NRs. These 
analyses revealed the basis for both ligand and DNA binding, and also revealed receptor 
conformations representing both the activated and repressed states. Additionally, crystallographic 
studies explained how NR LBD surfaces recognize discrete portions of transcriptional 
coregulators. The many structural snapshots of LBDs have also guided the development of 
synthetic ligands with therapeutic potential. Yet, the exclusive structural focus on isolated NR 
domains has made it difficult to conceptualize how all the NR polypeptide segments are 
coordinated physically and functionally in the context of receptor quaternary architectures. Newly 
emerged crystal structures of the PPARγ-RXRα heterodimer and HNF-4α homodimer have 
recently revealed the higher order organizations of these receptor complexes on DNA, as well as 
the complexity and uniqueness of their domain-domain interfaces. These emerging structural 
advances promise to better explain how signals in one domain can be allosterically transmitted to 
distal receptor domains, also providing much better frameworks for guiding future drug discovery 
efforts.
Introduction
As transcription factors, nuclear receptors (NRs) bind directly to lipophilic ligands, such as 
steroids, thyroid hormone, retinoids, and dietary lipids, and respond by regulating gene 
expression programs (Gronemeyer, et al. 2004; Mangelsdorf and Evans 1995; Mangelsdorf, 
et al. 1995). NRs have long been exploited as therapeutic drug targets. Molecules such as 
tamoxifen for estrogen receptors (ER) used for breast cancer, thiazolidinediones for 
peroxisome proliferator-activated receptor-gamma (PPARγ) used for type II diabetes, 
mifepristone for the progesterone receptor (PR) used for fertility, and dexamethasone for the 
glucocorticoid receptor (GR) used for inflammatory diseases, are among the prominent 
examples of prescription drugs that target NRs (Gronemeyer et al. 2004). By some 
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estimates, NR ligands constitute 10–20% of the worldwide pharmaceutical market (Ottow 
and Weinmann 2008).
With their remarkable property of transducing chemical signals from their ligands into 
changes in gene expression, structural biologists recognized early on the importance of 
obtaining mechanistic insights into how these polypeptides are folded and able to recognize 
their DNA and ligand molecules. For more than two decades now, structural efforts on 
discrete segments of NR have provided critical information regarding how ligands bind to 
the receptors with selectivity, which receptor conformations are consistent with the 
transcriptionally active or inactive states, how DNA recognition and receptor dimerization 
are achieved, and how different types of coregulators are recruited. Yet, our understanding 
of how the entire receptor polypeptides act in a concerted fashion using all of its domains, 
dimerization states, ligands and DNA, has only recently been unveiled through 
crystallographic advances. Here, we review the most important lessons learned from the 
crystallographic studies on individual domains, and also describe the newer findings based 
on nearly complete NR polypeptides arranged in their functionally revealing complexes.
Figures 1A–C show the domain arrangement of NRs within their polypeptides. NRs form a 
wide variety of dimeric states and bind to a variety of DNA response elements consisting of 
direct-repeat elements, palindromic (inverted) repeats, or extended monomeric sites (Figure 
1D). From these response elements, NRs then further recruit other complexes that bring 
repression or activation to their target genes (Figure 1C). The coregulator complexes that are 
recruited have the ability to modify histone tails and alter chromatin structure to promote or 
repress transcription. In the absence of ligands, some NRs recruit the binding of corepressor, 
such as nuclear receptor corepressor 1 (NCoR1) or silencing mediator for retinoid and 
thyroid hormone receptor (SMRT), which further recruit histone deacetylases (HDACs). In 
the activated state, NRs recruit coactivators that link the status of the ligand activated NRs to 
the chromatin state, by recruiting of complexes that differentially modify histone tails. The 
coactivator containing complexes typically harbor histone acetyltransferase (HAT) activity 
(Glass and Rosenfeld 2000; McKenna, et al. 1999). The DNA binding domain (DBDs) and 
ligand binding domains (LBDs) of most NRs are now relatively well understood 
structurally, and our understanding of their architecture and functional properties is 
summarized in this review. We also describe the more recent structural studies on multi-
domain NR complexes and what they have recently revealed about the higher order 
quaternary organization of NRs, and the possibility of allosteric communications in their 
complexes (Figure 2).
The DNA Binding Domain and Response Element Recognition
Early studies based on domain swapping and the characterization of DBD – DNA 
interactions suggested that this domain mediates the receptor’s entire ability to bind 
response elements in an independent and self-contained manner (Green and Chambon 1987; 
Kumar, et al. 1987; Umesono and Evans 1989). The centrally positioned DBDs were also 
recognized to be the most conserved segments of NR polypeptides, and accordingly they 
closely share the same overall three-dimensional structure, as shown in Figure 3A 
(Khorasanizadeh and Rastinejad 2001). Eight perfectly conserved cysteine residues 
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coordinate two zinc ions to maintain the overall core DBD fold, which encompasses a total 
of 66 amino-acid residues. Two alpha helices that pack in a perpendicular fashion are 
contained in this core unit, one of which is responsible for DNA half-site recognition. The 
binding of the zinc ions to the DBD was initially confirmed through an Extended X-ray 
Absorption Fine Structure (EXAFS) study (Freedman, et al. 1988).
The first structural characterizations of the isolated DBDs used nuclear magnetic resonance 
(NMR) based approaches focusing on the estrogen receptor (ER), glucocorticoid receptor 
(GR), and retinoic acid receptor beta (RARβ) (Hard, et al. 1990; Knegtel, et al. 1993; 
Schwabe, et al. 1990). These studies identified the secondary structural elements of the 
DBDs, and confirmed that the overall fold was highly similar in all three receptors. These 
key lessons derived from NMR studies were soon expanded by more comprehensive studies 
that used X-ray crystallography with ER and GR, in each case as a homodimeric DBD 
complex bound to DNA (Luisi, et al. 1991; Schwabe, et al. 1993). A key finding was that 
one helix inserts directly into the major groove of the conserved hexamers present in the 
DNA response elements. GR, PR, the androgen receptor (AR) and the mineralocorticoid 
receptor (MR) use the same consensus 5′-AGGACA-3′ conserved half-sites, whereas ER 
and most non-steroid receptor use 5′-AGGTCA-3′ half-sites. Accordingly, these two 
receptor groups also use distinct sets of amino acids on the exposed face of their DNA 
recognition alpha helices. As shown in Figure 3B, water molecules are very much involved 
in the DNA major groove interactions, and can also support the interactions of the DBD 
residues with the phosphate backbone of their response elements.
While the recognition alpha helix accounts for half-site binding, this type of interaction 
alone did not fully account for response element selectivity in the NR family. This is 
because there are only two major types of consensus DNA hexamers and there is a high 
degree of sequence conservation in the DBD amino-acid sequences within the family. Later, 
it became clear that DNA target selectivity relies in great part on the geometry associated 
with a response element when two half-sites are arranged in various bipartite fashions 
(Figures 1D and 4) (Mader, et al. 1993; Perlmann, et al. 1993; Umesono, et al. 1991). To 
recognize the geometry in their binding sites, dimeric receptors are required to cooperate on 
bipartite response elements as correctly paired homodimers or heterodimers. The DNA half-
sites can be arranged as direct-repeats or palindromic (inverted) repeats. Half-site spacing is 
crucial for establishing response element selectivity, since each additional spacer between 
the repeats displaces the half-sites by 3.4 Angstrom, and approximately 35 degrees, so that 
only the correct receptor pairs can interact productively.
Structural studies on multiple DBD-DNA complexes proved successful, as shown in Figure 
4 (Devarakonda, et al. 2003; Little, et al. 2006; Lu, et al. 2008; Meinke and Sigler 1999; 
Rastinejad, et al. 1995; Rastinejad, et al. 2000; Roemer, et al. 2006; Shaffer and Gewirth 
2002; Shaffer, et al. 2004; Sierk, et al. 2001; Solomon, et al. 2005; Zhao, et al. 2000; Zhao, 
et al. 1998). The dimeric complexes show that DBDs associate with significant cooperativity 
on their correctly configured DNA site. The basis for the binding cooperativity lies in the 
protein-protein contacts that the DBDs form within the spacer minor groove. The DBDs 
form these DNA-dependent dimer interfaces in a manner that does not interfere with the 
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proper registration of each recognition helix inside the DNA major grooves within the half-
sites (Luisi et al. 1991).
When the DNA is absent, DBD-DBD interactions cannot form, since the spacer minor 
groove is an active component in this dimerization process. Indeed, the minor groove 
provides a very sheltered environment for polar residues to interact between the two DBDs, 
without interference from bulk solvent. NMR studies carried on the GR DBD complex with 
DNA have suggested an allosteric communication pathway that signals between the DNA 
and the dimerization interfaces of the DBDs (Watson, et al. 2013). While structural studies 
involving DBD/DNA complexes have now shown why the three-base-pair spacing in a GR 
or PR response element is necessary for cooperative DBD interactions and DNA 
recognition, it remains to be explained how the selectivity in binding-site repertoires are 
generated for steroid receptor homodimers, since most of them use the same symmetry, 
spacing, and consensus half-site sequences (Luisi et al. 1991; Roemer et al. 2006). It is 
likely that other unique sites flanking the 3′ or 5′ half-sites of these symmetric repeats allow 
for selectivity, a notion that was supported by the crystal structure of progesterone receptor 
(PR) DBD on DNA (Nelson, et al. 1999; Roemer et al. 2006). Moreover, other bipartite 
configurations of the consensus half-site motifs, or possibly other collaborating transcription 
factors, are likely to provide additional specifying queues for establishing response element 
selectivity physiologically.
The retinoid X receptor (RXR) proved to be a special member of the nuclear receptor 
family, since it could form heterodimers with a variety of non-steroid receptors (Bugge, et 
al. 1992; Forman, et al. 1995; Hallenbeck, et al. 1992; Kliewer, et al. 1992a; Kliewer, et al. 
1992b; Leid, et al. 1992; Marks, et al. 1992; Yu, et al. 1991; Zechel, et al. 1994a; Zechel, et 
al. 1994b). The dimerization partners of RXR include the retinoic acid receptor (RAR), 
Vitamin D3 receptor (VDR), thyroid hormone receptor (TR), PPAR and several other 
receptors (Figure 1D). As with the steroid receptors, the DBDs of RXR and its 
heterodimeric partners are unable to efficiently interact in the absence DNA. But in presence 
of correct response elements, they produce the same patterns of DNA selectivity as their 
full-length receptors. The RXR heterodimers use high-affinity response elements consisting 
of direct-repeats (DRs) with distinct half-site spacings (Mader et al. 1993; Perlmann et al. 
1993; Umesono et al. 1991). These spacings range between one to five base pairs (with their 
corresponding DR elements referred to as DR1–DR5). The pattern of site selectivity based 
on the spacing of DRs is known as the 1–5 rule (Umesono et al. 1991). Whereas RXR can 
form DBD-DBD interactions productively with a partner such as TR on DR4, a change in 
the spacing size would block these interactions, causing RXR to require a different 
heterodimerization partner instead. Curiously, the RXR homolog in Drosophila, known as 
ultraspiracle (Usp) uses a palindromic DNA site, instead of direct repeats, to form a 
heterodimer with the ecdysone receptor (EcR), as shown in Figure 4.
In contrast to palindromic binding sites used by steroid receptor homodimers, the individual 
half-sites in a direct-repeat element can further be distinguished according to their upstream 
or downstream location. In RXR heterodimers, RXR can be positioned alternately at the 
upstream or downstream half-site relative to its partner. RXR–RAR complexes on DR1 and 
DR5 form with opposite polarity and these, in turn, have different responses to ligands and 
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co-repressors(Kurokawa, et al. 1994). Structural studies confirmed that RXR could bind to 
opposing half-sites depending on the choice of its heterodimerization partners. Figure 4 
shows the RXR-RAR DBD complex in which RXR is positioned downstream of its partner, 
and the RXR-TR DBD heterodimer, where RXR is positioned upstream of its partner 
(Rastinejad et al. 1995; Rastinejad et al. 2000). In the full-length RXR-PPAR heterodimer 
on DR1, RXR was found located on the downstream half-site (Chandra, et al. 2008). As 
with the steroid receptors, structural studies on RXR DBD heterodimers have also taught us 
that the DBDs form their protein-protein interactions inside the minor groove of the spacer 
(Rastinejad et al. 1995; Rastinejad et al. 2000; Zhao et al. 2000). An important lesson from 
these studies is that the interactions between the DBDs of RXR and its partners are not hard-
wired. Instead, they are adaptable to their DNA binding sites and can undergo induced fit at 
locations required for dimerization and minor groove binding.
Within the context of the full-length receptors, it was also suggested that the relative 
location of the two receptors could have profound consequences, in terms of constraining 
the patterns of domain-domain interactions and the response to ligands. The potential 
consequences on the quaternary organization were recognized to include the possibility of 
restricting one partner from interacting with ligands or coregulators (Kurokawa et al. 1994). 
Since RXR heterodimers with many NRs, another intriguing issue has been whether each 
member of a heterodimer needs its own ligand for the heterodimer to be active (Germain, et 
al. 2002). Indeed, RXR can act as a silent or an active partner in these heterodimers. In 
RAR/RXR, TR/RXR and VDR/RXR heterodimers, there is little or no transcriptional 
activity without the RXR ligand, and these are referred to as “non-permissive” complexes, 
as ligands for both heterodimeric partners are required. In “permissive” complexes, such as 
PPAR/RXR, LXR-RXR and FXR-RXR, ligands for either partner are sufficient for robust 
transcriptional activation (Germain et al. 2002). The permissive status of the PPARγ -RXR 
heterodimers has allowed for RXR binding agonists to be developed that would show 
similar actions physiologically as PPARγ ligands, such as in sensitizing diabetic mice to 
insulin (Mukherjee, et al. 1997).
While many NRs rely on dimeric arrangements, some receptors bind to DNA as monomers 
and function without partners (Figure 4). Monomeric receptors include NGFI-B (also known 
as NURR77), Rev-Erb, ROR and SF-1 (Figures 1D and 4) (Charles, et al. 1999; Giguere, et 
al. 1995; Harding and Lazar 1995; Wilson, et al. 1993). The Rev-Erb DBD/DNA crystal 
structure first showed how a DBD could rely on a portion of the NR hinge region, named the 
C-terminal extension (CTE) of the DBD, to extend its DNA binding footprint for efficient 
monomeric binding (Zhao et al. 1998). The site of the DNA contacted by the CTE is 
positioned directly upstream of the single consensus half-site. An examination of Rev-Erb 
CTE sequences alongside other NR CTE sequences suggested how certain other NRs would 
similarly recognize extended half-sites (see Figure 3A) (Zhao et al. 1998). Later studies on 
nerve growth factor-induced B (NGFI-B) and liver receptor homolog-1 (LRH-1), and 
steroidogenic factor-1 (SF-1) DBDs verified the predicted mode of minor groove 
interactions by their CTE, which always involved the 5′ extension of the half-site (Little et 
al. 2006; Meinke and Sigler 1999; Solomon et al. 2005). In receptors that form dimeric 
arrangements on DNA, the CTE regions can also have the important role of acting as a 
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“ruler”, by measuring the size of the inter-half-site spacer to ensure that a heterodimer is 
using its correctly spaced response element (Rastinejad et al. 1995; Zhao et al. 1998).
The Ligand Binding Domains and the concept of Receptor Activation
The NR LBDs have a similar overall conformation consisting of a three-layered helical 
sandwich. The LBD is characterized by a hydrophobic cavity or pocket in which lipophilic 
ligands are captured and shielded from the solvent environment. While the overall 
architectures of NR LBDs may look strikingly similar, the ligand pockets within these LBDs 
are sufficiently unique in size and character, with diverse amino-acid compositions that 
ensure specificity for endogenous ligands. Given that the endocrine steroid receptors, 
vitamin D receptor (VDR), liver X receptor (LXR) and Farnesoid X receptor (FXR) 
recognize ligands that have a similar overall cholesterol derived chemical frame, it is 
remarkable that these pockets so clearly exclude all but the correct ligands for each receptor. 
When examined as a group of 48 human NRs, the LBD pockets have a volume from zero 
(i.e. totally absent due to the pocket being filled with hydrophobic side chains from the 
LBD), to more than 1500 Å3 (Li, et al. 2003). Non-polar residues predominantly line these 
pockets, with one or more polar residues also present in the pocket that form effective 
hydrogen bonding with hydrophilic groups that may be present on some NR ligands. The 
pockets discriminate their ligands using van der Waals forces to detect the surface and shape 
features of lipophilic ligands.
The three dimensional crystal structures of most of the 48 NR LBDs have been deposited in 
the protein data bank (PDB). Notable exceptions are the homologue of the Drosophila 
tailless gene (TLX), the neuron-derived orphan receptor 1 (NOR-1), the photoreceptor cell-
specific nuclear receptor (PNR), and the germ cell nuclear factor (GCNF). Most of 
crystallized LBDs could only be studied in the liganded state (Gronemeyer et al. 2004; 
Huang, et al. 2010; Nagy and Schwabe 2004). There are fewer unliganded LBD crystal 
structures because the absence of the ligand typically destabilizes the LBD polypeptide, 
making it challenging to crystallize. RXRα, PPARγ, NURR1, the estrogen-related receptor γ 
(ERRγ), the pregnane X receptor (PXR), LRH-1, TR4 and COUP-TFII are among the 
human unliganded LBDs that were structurally characterized (Bourguet, et al. 1995; 
Greschik, et al. 2002; Kruse, et al. 2008; Nolte, et al. 1998; Sablin, et al. 2003; Wang, et al. 
2003; Watkins, et al. 2003; Zhou, et al. 2011). Figures 5–8 show some of the general 
features of LBDs. A key observation was the conformational switch that is shown in Figure 
5A. This switch was described in the context of the retinoic acid receptor LBDs, by 
comparing the apo-state to the liganded-state. The actual basis for developing this concept 
came from separate X-ray crystallographic studies on different receptor, one being the apo-
RXR LBD and the second being liganded RAR LBD (Bourguet et al. 1995; Renaud, et al. 
1995; Wurtz, et al. 1996). In this model, activating ligands reposition helix 12 (H12), as well 
as causing smaller rearrangements elsewhere (Nagy and Schwabe 2004). In the unliganded 
state, H12 is far away from the body of the LBD, and in the liganded and active state it 
moves proximal to the ligand, helping to trap it in the pocket as in a mouse-trap (Wurtz et al. 
1996).
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Despite the elegance of the mousetrap mechanism for receptor activation, further 
examination of NR unliganded structures could not show any other NR that used the same 
mousetrap mechanism. More typically, it was observed that H12 appeared to be in the active 
conformation closing atop the ligand, even in the absence of ligand in the cavity (Nagy and 
Schwabe 2004). Therefore, an alternative “dynamic stabilization” model was evoked to 
describe the differences between the active and inactive states of LBDs. In the apo-state, 
H12 is not fixed in any one single position, but rather mobile along with other portions of 
the LBD, resembling a molten state. Ligands stabilize the receptor fold globally, lowering 
the degree of conformational dynamics overall including fixing H12 in stable position and 
stabilizing the surface elements required for coactivator binding. If a receptor without ligand 
is already conformationally stable, then it is likely to show constitutive transcriptional 
activity. This notion appears to be supported for a subset of NRs exemplified by NURR1, 
which are constitutively active, and also have a highly stable conformation in the apo-state 
(Wang et al. 2003).
In other NRs that require ligand binding for activation, ligand filling of the interior often 
stabilizes the global conformation and lowers the dynamic motions on the LBD surface. The 
LBD surface is precisely where coactivators bind, and a groove is needed on the surface to 
capture the interacting portion of coactivators (Figure 6). The dynamic stabilization model 
of receptor activation has been well supported by a variety of biophysical and biochemical 
methods. For example, fluorescence studies showed that H12 is more dynamic in the apo-
PPARγ LBD, compared to the liganded state of this protein (Kallenberger, et al. 2003). In 
the standard view of receptor LBD structures, as shown in Figures 5–8, the lower portion of 
the LBD is more “molten” than the top portion of the LBD, when ligands are absent. 
Support for this concept comes from NMR studies, as well as the crystallographic 
temperature (B) factors of these regions in LBD structures (Johnson, et al. 2000; Nolte et al. 
1998). Proteolytic sensitivity studies, as well as secondary structure melting studies on 
LBDs further support the concept that ligand activation switches a relatively unstable LBD 
fold to a more rigid and well-ordered conformation (Keidel, et al. 1994; Leng, et al. 1993; 
Nagy and Schwabe 2004; Pissios, et al. 2000; Raghuram, et al. 2007).
Given the potential importance of LBD dynamics to receptor activation, it is important to 
point out that crystallographic methods are not well-suited for obtaining dynamic 
information about protein structures, instead capturing “snapshots” of structurally stable 
states of macromolecules. NMR and hydrogen-deuterium exchange mass spectrometry (H/D 
EMS) applied to some NRs proved much better at characterizing the dynamic states of these 
proteins (Johnson et al. 2000) (Bruning, et al. 2007; Dai, et al. 2009; Hughes, et al. 2012; 
Zhang, et al. 2010). H/D EMS has proven to be a particularly powerful tool in this regard, 
because it can be successfully applied to large NR complexes consisting of all the domains, 
dimerization partners and DNA, as exemplified in the case of RXR-PPAR and RXR-VDR 
full-length complexes. (Chandra et al. 2008; Zhang, et al. 2011). Thus far, NMR studies 
have been limited to truncated complexes of NRs. As the molecular weight of the 
polypeptide increases, the signal overlap and slower tumbling dynamics of the complex 
prohibits analysis by NMR.
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Whether one subscribes to the mousetrap mechanism or the dynamic stabilization model, the 
importance of the H12 structure for receptor activation remains central. This is because in 
the active form of receptors, attained constitutively or through ligand binding, H12 
participates directly in recruiting and stabilizing coactivators onto the surface of the LBD 
(Figure 6). This helix largely accounts for the activation-function 2 (AF-2) associated with 
the LBD, that is ligand-dependent. In some NRs, the A/B or N-terminal domain (NTD) 
regions of NRs are associated with an activation function-1 (AF-1), which is not dependent 
on ligand binding and can also assist in the recruitment of coactivators. In the AR, there is 
evidence for physical interaction between the NTD and LBD that is important for binding of 
coactivators (He, et al. 2000).
Because both coactivators and corepressor recognize LBDs, it is also important to keep in 
mind the issue of matching the stoichiometry of coregulator binding to dimerization status of 
NR complexes. Many coactivators and corepressor contain more than one interacting motif 
within their polypeptides(Heery, et al. 1997). In the case of coactivators, proteins such as 
steroid receptor coactivators (SRCs) contain three or more leucine rich, LXXLL motifs 
within a single polypeptide (Darimont, et al. 1998; Heery et al. 1997). Similarly, 
corepressors can possess multiple LXXXLXXX[I/L] motifs, known as CoRNR boxes, 
within their polypeptides (Hu and Lazar 1999). We discussed above how NRs can use their 
DBDs to form DNA-dependent dimerization interfaces. The LBDs too can, in some cases, 
form LBD-LBD interfaces, doing so independent of DNA as shown in Figure 5B. Note that 
LBD-LBD dimerization interfaces form through similar helices, whether one examines RXR 
heterodimers or the steroid receptor homodimers. Since coregulators have multiple leucine 
rich motifs, they may attach a single copy of this motif to just one partner of the dimer, or 
use two motifs to contact both NR partners simultaneously. For each of the homodimeric 
ERRα or ERRγ receptors, an asymmetric coactivator binding mode appears to be used, 
where just one subunit of the homodimeric receptor interacts efficiently with an interacting 
region from the peroxisome-proliferator-activated-receptor gamma coactivator 1α (PGC-1α) 
protein (Devarakonda, et al. 2011; Takacs, et al. 2013).
The manner by which most coactivator LXXLL motifs tend to form amphipathic alpha-
helices and bind to receptor LBDs in a H12 dependent manner was first seen in the crystal 
structures of PPARγ and ER (Nolte et al. 1998; Shiau, et al. 1998). Those observations have 
since been revisited in the structures of many other NR LBDs in their active states with 
LXXLL peptides. In the example provided in Figure 6, we show how the binding of RORβ 
to an activating ligand (all-trans retinoic acid) leads to a LBD conformation with H12 
becoming ordered atop the ligand cavity (Stehlin-Gaon, et al. 2003). From this position, H12 
physically supports the interactions with the coactivator motif. While the structure of the 
unliganded RORβ is unavailable, one could reasonably infer that due to significant dynamics 
of H12, the LXXLL binding would be prohibited in the apo-state. Figure 6 further shows 
how face-down interactions of the leucine residues in the LXXLL motif form with respect to 
a hydrophobic groove on the LBD surface. An accessory clamp mechanism is sometimes 
used for stabilization of the LXXLL motifs on LBDs. The charge clamp involves the 
participation of a lysine (basic residue) and glutamate (acidic residue) from some LBDs 
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interacting with the dipole of the leucine -rich helix (Bledsoe, et al. 2002; Mak, et al. 1999; 
Nolte et al. 1998).
Some NR ligands, such as rosiglitazone are able to directly contact amino acids located on 
the H12 helix, firmly stabilizing this helix in the active state. But structural studies show that 
most often ligands indirectly stabilize H12 through intervening residues, as the pocket is too 
far from H12 to allow for the ligand to interact directly (Huang et al. 2010). Synthetic NR 
ligands have been described with a wide spectrum of activities, comprising full agonists, 
partial agonists, antagonists and selective gene modulators. How these molecules shape 
different receptor activities is not only a consequence of their binding mode, but also 
dependent on the type and ratio of coactivators versus corepressor in a cell type and during a 
physiological state. Because NRs typically control hundreds or thousands, of genes in one or 
more cell types, the development of receptor agonists or antagonists for therapeutic benefit 
has proven difficult. A ligand can produce many unintended physiological side effects due 
to the multitude of gene targets. For this reason, selective modulators are often sought, with 
the idea that these molecules could control selective gene programs, and not every gene 
target (Huang et al. 2010). For other disease indications, such as for treatment of breast or 
prostate cancers that depend largely on the activity of a single NR, potent antagonists may 
be more acceptable and the development of such compounds has been productive.
Elegant principles for rationally converting a receptor agonist to an antagonist were 
introduced through the crystallographic characterizations of estrogen receptors (ERs) 
(Brzozowski, et al. 1997; Shiau et al. 1998; Tanenbaum, et al. 1998). Those crystallographic 
studies were then followed by more ER LBD structures that were in complex with diverse 
ligands, better advancing our understanding of how agonism, partial agonism, and 
antagonism is achieved with NRs (Pike, et al. 1999; Pike, et al. 2000; Pike, et al. 2001). 
Since multiple aspects of mammalian growth, differentiation, reproductive function, as well 
as heart, bone and liver physiology are regulated through ERα and ERβ, therapeutic 
targeting of these receptors was recognized as an important goal for developing breast 
cancer, osteoporosis and obesity treatments (Deroo and Korach 2006).
Figure 7A–C illustrates some of the most important lessons unveiled through the early 
structural studies with both estrogens and synthetic molecules that competed for the 
endogenous ligand of ERα, 17-β-estradiol. Estrogen and the synthetic ligand 
diethylstilbestrol (DES) are both agonists, causing ERs to be transcriptionally active. As 
shown in Figure 7B, these agonists bind inside the LBD cavity and position H12 in its active 
conformation. By contrast, molecules such as tamoxifen and raloxifene still use the common 
DES chemical frame but with the presence of their large, bulky side-chain extension, instead 
act as ER antagonists, shutting off the transcriptional activity. Tamoxifen has been used 
widely for clinical treatment of breast cancers. Raloxifene was developed for its protective 
effects on bone and its anti-proliferative effects on breast cancer cells. While most of the key 
amino acids in the ER pocket responsible for binding these agonists and antagonists are 
identical, the side-chain extensions of the antagonists point in the direction of H12 and 
displace it away from the active position (Figure 7B–C).
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A different set of structural studies shaped our understanding of how corepressors physically 
interact with NR LBDs. Figure 8A–B show structures of PPARα with both an agonist 
(GW731) and an antagonist (GW6471) (Sierra, et al. 2007; Xu, et al. 2002). The corepressor 
uses the same location that is occupied by H12 and the LXXLL motif, when the receptor 
would be in the activated state. The mutually exclusive binding of these two types of 
coregulators, is an important principle revealed from these crystallographic studies. Another 
crystallographic characterization of the unliganded Rev-Erbα LBD bound to a N-CoR 
peptide shows the interactions of a beta-strand together with an alpha-helix from the 
corepressor (Figure 8C) (Phelan, et al. 2010). The occupied position of the corepressor motif 
is still similar to the binding site of the corepressor motif seen within the PPARα structure. 
The two Rev-Erb receptors (α and β) use heme as their endogenous ligands (Pardee, et al. 
2009; Raghuram et al. 2007; Yin, et al. 2007). Even with heme bound, the Rev-Erbs are not 
known to interact physiologically with coactivators. Still, a comparison of the heme-bound 
Rev-Erbβ with the apo-Rev-Erbα/corepressor complex indicated that heme binding would 
interfere with the binding of the corepressor motif (Phelan et al. 2010).
Another area that benefited from structural studies has been the discovery of receptor 
subtype selective ligands (Huang et al. 2010; Nilsson, et al. 2011). ERα and ERβ are distinct 
gene products with non-redundant physiological functions (Gustafsson 2003). ERα and ERβ 
regulate different classes of genes by associating with distinct response elements and by 
recruiting different coregulator complexes (Leitman, et al. 2010). Selective modulation of 
ER activity can be achieved in part through selective modulation of one receptor subtype 
over the other. ERα has been an excellent target for breast cancer therapy using molecules 
that act as ER antagonists in breast tissue. Agonists could also be potentially valuable for 
other therapeutic benefits, including osteoporosis, inflammatory and neurodegenerative 
diseases (Nilsson et al. 2011). But the activation of ERα imposes an increased risk for the 
development of breast or endometrial cancer, making agonists more risky for development. 
ERβ-selective agonists would be advantageous, as they are not expected to stimulate the 
proliferation of breast or endometrial tissues (Nilsson et al. 2011). But with the two ERs 
using very similar amino acids in their ligand pocket, can selective ligands really be found? 
There are seven key amino-acids lining the pockets of each receptor, and differences in only 
two of these residues when one compares ERα to ERβ (leucine vs. methionine, and 
methionine vs. isoleucine) (Huang et al. 2010). Still, a number of molecules have been 
developed using structure-guided principles that exhibit reasonably selective preference for 
ERα over ERβ (Stauffer, et al. 2000; Sun, et al. 2002; Sun, et al. 1999). Other synthetic 
molecules have been shown to be selective for ERβ over ERα (Manas, et al. 2004; Sun, et al. 
2003). A nice example is the molecule diarylpropionitrile (DPN), which acts as an ERβ 
selective agonist. Functional assays the relied on ERα/ERβ chimeras and residue-specific 
mutagenesis, together with molecular modeling analysis, point to a single residue in the ER 
pocket (Met 366) as being largely responsible for the ERβ selectivity of DPN (Sun et al. 
2003).
There are other NR subfamilies that consist of multiple members, including the retinoic acid 
receptors (three RARs) and thyroid hormone receptors (two TRs), where subtype selective 
ligands are sought. While both TRα and TRβ bind to triiodothyronine with high affinity, 
they elicit different physiological responses. TR ligands, aside from their use in thyroid 
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hormone replacement therapy, can potentially be beneficial in lowering serum LDL, 
cholesterol and triacylglycerol levels, but only if their other effects on heart, bone and 
muscle can be minimized (Baxter and Webb 2009). Several modulators have been described 
with 4–10 fold selectivity toward TRβ over TRα, and developed using crystallographic 
guidance (Wagner, et al. 2001). The two TR receptors have pockets differing in only a 
single amino-acid residue (Huang et al. 2010). In the case of the three RARs, there are three 
amino-acids that differ in the pockets. For RARs also, small molecules that exhibit selective 
binding to each receptor have been discovered using structure insights (Germain, et al. 
2004).
While many NRs use steroids and related cholesterol derived molecules as their endogenous 
ligands, it is worth pointing out how differently these molecules can be oriented and 
captured within NR respective pockets. In steroid receptors, the cognate ligands can bind 
with single digit nanomolar affinity. In the case of LXRs and FXR, oxysterols and bile acids 
bind in the micromolar Kd range, respectively (Huang et al. 2010). Yet the ligand affinities 
of LXR and FXR still match the physiological concentrations of these molecules in tissues 
such as liver and intestine, making these receptors physiologically responsive. Figure 9 
demonstrates how FXR and LXRα/β, two closely related NRs with a common LBD 
architecture, orient their related ligands in opposing directions within their pockets. In the 
case of FXR, the steroid ring A of chenodeoxycholic acid (CDCA) is positioned to point 
toward H12, whereas in the LXRs the D-ring and epoxide tail of epoxycholesterol are 
pointed toward H12 (Mi, et al. 2003; Williams, et al. 2003).
This striking difference in ligand recognition points to the incredible diversity and 
adaptability of NR LBD pockets. There are many examples showing how a single NR 
pocket can undergo significant readjustment to allow for the binding of various synthetic 
ligands. We demonstrate this principle with the example shown in Figure 10. This example 
shows how the GR pocket accommodates an agonist (dexamethasone) or two significantly 
larger antagonists using side-chain rearrangements within the pocket (Biggadike, et al. 2008; 
Bledsoe et al. 2002; Kauppi, et al. 2003). The GR pocket clearly undergoes induced fit, 
expanding from a volume of 540 Å3 to more than 1000 Å3 to make the necessary 
accommodations for all of these ligands. Such findings underscore the plasticity by which a 
single LBD pocket adapts to ligands with a broad range of chemical scaffolds and functional 
groups.
Structures of Full-Length and Multi-Domain Receptor Complexes
Despite multiple DBD-DNA structural characterizations and hundreds of LBD-ligand 
structural characterization, there was no reported success in visualizing the higher order 
architectures of NRs using crystallography until 2008 (Chandra et al. 2008; Chandra, et al. 
2013). For that reason, the physical understanding of how these domains interact and 
potentially communicate lagged in the field. For other transcription factor families too, 
visualization of multi-domain or complete polypeptides has rarely proved successful by 
crystallographic means. There too, most structural biologists study the isolated single 
domains since they tend to crystallize easier. For NRs, several functional and biochemical 
studies were nevertheless showing us that NR domains were integrated and not like 
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individual beads on a string. In the case of ER, DNA binding at the DBD was shown to alter 
the ligand directed activities at the LBD (Hall, et al. 2002). The DNA binding in ER could 
also modulate coactivator binding at the LBD (Hall et al. 2002). In the glucocorticoid 
receptor, DNA binding could impact receptor structure and activity at the LBD (Lefstin, et 
al. 1994; Lefstin and Yamamoto 1998; Meijsing, et al. 2009). In the androgen receptor, there 
was also biochemical evidence for DBD communication to the LBD (Helsen, et al. 2012). 
Several synthetic ligands were demonstrated to cause significant changes in the DNA 
affinity of NRs, even though they bound to the LBD, again suggestive of DBD-LBD 
communications via domain-domain interactions (Clegg, et al. 2012; Huh, et al. 2011).
Despite longstanding efforts at visualizing the multi-domain arrangements of NRs using 
high-resolution methods, many technical barriers had remained. First, there was the 
difficulty in obtaining large quantities of stable, intact proteins in soluble form. Second, 
there are disordered receptor segments, especially when NRs are not in their assembled 
complexes with DNA and coregulator portions. Third, there is the difficulty in knowing 
which combination of ligands, peptides and DNA would produce the stable, well-behaved 
complex suitable for crystallization. We adopted numerous strategies in attempting to 
overcome each of these difficulties. These proteins can be obtained through recombinant 
expression methodologies that employ E. coli, SF-9/baculovirus, or transient transfection in 
HEK-293 or other mammalian cells. Conditions for ensuring the correct folding and 
maximal solubility of NRs are then identified by testing a battery of receptor ligands for 
their ability to enhance the soluble protein yield during recombinant expression. To 
minimize receptor segmental disorder, one can take advantage of H/D EMS information, or 
proteolytic mapping experiments to identify combinations of NRs, ligands, coactivators and 
DNA duplexes that produce stable complexes. Finally, size-exclusion chromatography is 
applied to isolate in a single fraction, the pre-ordered multi-component complexes of NRs. 
This latter step ensures the correct stoichiometry of components in a single elution peak, 
which facilitates successful crystal growth.
We first described the complete structural organization and domain couplings of the intact 
PPARγ-RXRα heterodimeric complex (Chandra et al. 2008). The complex architecture is 
shown in Figure 11, and was crystallized with DR+1 DNA and coactivator LXXLL peptides 
bound to both receptors, a retinoid molecule bound to RXRα, and several different ligands 
bound to PPARγ receptor. It became clear that the NR domains were intimately coupled and 
coordinated, as opposed to being loosely connected and independent domains. A close look 
at the top panel of Figure 11 suggests it is hard to identify the individual domains in the 
PPAR and RXR receptors, as they are so intertwined. The PPARγ LBD occupies the 
centerpiece of the entire heterodimeric complex to directly contact all other ordered domains 
from both RXRα and PPARγ (Figure 11).
We identified a total of three distinct heterodimerization junctions that had formed between 
RXR and PPAR, one of which had remained uncharacterized through previous studies 
utilizing isolated DBDs and LBDs. Therefore, not only were the domains interacting within 
a single receptor polypeptide, but also some domains were interacting across the 
heterodimeric partners. A number of other striking observations were made: a) Two of the 
three heterodimeric interfaces were controlled by the DNA, b) the PPAR LBD contributed 
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physically to DNA binding of both PPAR and RXR, c) the hinge region of PPARγ provided 
a significant degree of DNA recognition and established the polarity of the complex, and d) 
Information at the PPARγ-LBD (such as ligand or mutations) could in principle be 
transmitted to the DNA reading heads of the complex, due to domain-domain couplings. The 
analysis made clear that discrete DBDs and LBDs could no longer be perceived as self-
contained or independently functioning units. In other words, the whole receptor was 
functionally integrated in ways that were not previously imagined.
Along with many unanticipated findings in the PPARγ-RXRα complex, some 
reconfirmations of past lessons were also revealed. For example, the LBD-LBD interface of 
the heterodimer involved the same specific contacts previously described by those who 
crystallized the heterodimeric LBD complex of these two receptors (Nolte et al. 1998). The 
DBD-DBD interface too looked strikingly similar to the RAR-RXR DBD structure we had 
previously described on DR1 (Rastinejad et al. 2000). The polarity of the complex on DNA 
matched the biochemical findings previously predicted, including a role for the CTE in 
binding to the minor groove of DR1 (Zhao et al. 1998). The insertion of the DNA 
recognition helix of each receptor in the major grooves of the 5′-AGGTCA-3′, also 
conformed to previously established findings from DBD/DNA structures (Khorasanizadeh 
and Rastinejad 2001). The mode of ligand binding and LXXLL peptide binding closely 
matched what was seen with individual LBD structures previously studied (Nolte et al. 
1998). These reconfirmations point to the validity of the full-length crystal structure of the 
PPAR-RXR, and provide confidence in the overall representation described. Moreover, the 
H/D EMS studies carried out on the full-length PPAR-RXR /DNA complex, as well as 
mutations analysis of the key domain-domain interfacial junctions, support the 
crystallographic interpretations of this complex (Chandra et al. 2008)
To study other NR complexes, we next focused on the obligate homodimeric complex of 
HNF-4α on its cognate DR1 response element. HNF-4α is the most abundant transcription 
factor in the liver (Sladek, et al. 1990). Targets of this receptor include genes involved in the 
gluconeogenesis and lipid metabolism (Bolotin, et al. 2010; Fang, et al. 2012; Yoon, et al. 
2001). In the pancreas, HNF-4α is believed to control some 11% of islet genes (Bartoov-
Shifman, et al. 2002). HNF-4α dysfunction has been linked to a number of pathologies, 
including metabolic syndrome (Yin, et al. 2011). Specific point mutations in the HNF-4α 
protein can cause maturity onset of diabetes in the young-1 (MODY1), a monogenic form of 
diabetes, as well as hyperinsulinemic hypoglycemia (HH), a neonatal disease marked by 
unregulated insulin secretion with hypoglycemia (Kapoor, et al. 2008; Ryffel 2001). Since 
our efforts to crystallize the full-length HNF-4α proved unsuccessful, we instead 
crystallized and solved the structure of a slightly truncated, multi-component fragment of 
this receptor with DNA and coactivator peptides.
Our crystallographic findings showed that the HNF-4α homodimer also used multiple 
domain-domain junctions, integrating its various receptor functions (Figure 11). A striking 
convergence zone that we refer to as the “nerve center” lies at the center of this complex. 
This is the site where LBDs, the upstream positioned DBD, and the hinge region of one 
receptor subunit, all converge together. These connections provide a clear path for signal 
communications from one end of the complex to the other. The LBDs, which are 
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symmetrical in their mutual interactions, straddle the surface of only the upstream DBD. 
This arrangement breaks the overall symmetry of the heterodimer. The complex is 
partitioned in the direction of the upstream half-site of the DR1, and not symmetrically 
disposed over the entire DR1. This type of quaternary arrangement favorably allows both 
DBDs to still engage their AGGTCA half-sites and form a productive DNA-dependent 
dimerization interface within the minor groove of the DR1 spacer.
The observed quaternary organization in the HNF-4α homodimeric complexes also allows 
both LBD pockets to access and obtain ligands. Both LBD surfaces have exposed 
coactivator surfaces, where the LXXLL peptides are appropriately bound. Each of the 
HNF-4α LBDs has electron density belonging to a trapped a fatty acid with 14–16 carbon 
atoms. The associated fatty acid is believed to be an unusual ligand, providing structural 
stability to the HNF-4α/γ subfamily and not acting as an activation signal. Fatty acid 
molecules act in a similar fashion for other NRs, such as SF-1 and LRH-1 (Krylova, et al. 
2005). Interestingly, HNF-4α can be regulated by post-translational modifications (PTMs), 
and no ligand has been decisively shown to regulate all of its transcriptional activities.
Given the closely knit connections between multiple domains in this complex, we used other 
studies to explore allosteric communications within the HNF-4α complex (Chandra et al. 
2013). One good test for allosteric communications came from a close look at the MODY1 
point mutations. We found that many of these mutations mapped near the “nerve center”, 
suggesting that their impact could be transmitted from the domain on which they occur, to 
other distal domains. When we examined the MODY1 mutations positioned on the LBD, we 
could see that they had a strong impact on the DNA binding affinity of the receptor, even 
though they were not themselves positioned on the DBD (Chandra et al. 2013). Other 
mutational changes that we made at the LBD, which were not representative of MODY1 
mutations, could still be efficiently communicated to alter the DNA-binding affinity, 
consistent with an allosteric communication system.
A second mode of signal propagation from one domain to another came from the 
examination of several well-characterized PTMs that had been shown by others to control 
DNA binding affinity. We found that a methylation site (Arg-91) and a phosphorylation site 
(Ser-78) could be mapped onto positions directly at the “nerve center” (Chandra et al. 2013). 
Consistent with our crystallographic findings, Arg-91 methylation had been known to act as 
glue to lock-in the active quaternary organization that is capable of high affinity DNA 
binding. Ser-78 phosphorylation was known to cause a loss in DNA binding, and in this 
structure introduces unfavorable charge repulsion at the nerve center when phosphorylated, 
so as to disengage the quaternary structure required for efficient DNA binding. Mutational 
studies further confirmed many of the striking features of the quaternary organization. For 
example, Figure 11 shows the LBDs are participating in DNA binding by firmly holding a 
DBD atop the DNA. Binding studies confirmed that the LBD containing HNF-4α 
polypeptide binds to DR1with nearly 100 fold better affinity than the DBD alone (Chandra 
et al. 2013).
A comparison of the PPARγ-RXRα structure with the HNF-4α structure demonstrated that 
these two complexes were forming very different quaternary organizations, even though all 
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the DBDs and LBDs were conserved in fold, and both complexes were bound to the same 
DR1 response element. We envision that different members of the NR family would also 
display distinct arrangement of inter-domain junctions, allowing for unique modes of 
allosteric communications across their polypeptides. Furthermore, while the response 
element type is important for stabilizing the quaternary organization of the receptors, 
numerous other factors also drive the overall NR quaternary organization. Sequences and 
sizes of the hinge regions, as well as the residues on the outside of the LBDs that are not 
conserved, can all participate in producing unique quaternary architectures for each NR 
complex. We also found in both complexes that the NTDs were not observed, due to a lack 
of structural order or failure to interact with other receptor segments. The NTD portions 
have been shown to be functionally important for gene activation in some receptors, but 
have consistently failed to show structural order when examined alone or in the context of 
entire polypeptides. Invoking the concept of induced folding, it is possible that A/B 
segments become folded only upon interactions with specific coregulators that assemble in 
the active or repressed complexes. The H/D EMS study carried out on the PPAR A/B 
domain, alone and in the presence of its dimeric partner RXR and DNA, also failed to find 
ordered regions.
While crystallography has so far proven the most powerful tool for visualizing the physical 
molecular interactions in full-length NRs, electron microscopy and solution biophysical 
methods are also adding low resolution (10–30 Angstrom resolution) information (Orlov, et 
al. 2012; Rochel, et al. 2011). These studies provide information in terms of broad molecular 
envelopes that can help one to position well-ordered domains relative to each other. But due 
to their far lower resolution, such studies cannot reveal the basis for allosteric 
communications in a nuclear receptor complex. H/D EMS can provide more specific 
information regarding allostery and signal propagation from one domain to another. A study 
carried out on the VDR-RXR full-length receptor complex has successfully uncovered how 
DNA binding alters receptor dynamics in regions far from the DBDs, including the 
coregulator binding surfaces of both receptors (Zhang et al. 2011). Future studies based on 
high resolution structure characterizations combined with dynamics information will 
continue to show how interfacial surfaces in other NR complexes allow signals to be 
communicated allosterically across receptor complexes.
CONCLUSIONS
As major transcriptional regulators controlling development, endocrine signaling, 
metabolism, and circadian rhythms, the NR polypeptides are remarkably efficient at 
integrating small molecule binding with DNA interactions and transcriptional regulation. 
This view suggests that NRs must indeed have integrated domains that communicate 
information from one part of their polypeptides to another. Until recently, all previous 
structural efforts were more focused and successful with individual DBDs and LBDs. 
Through those studies, we have come to appreciate importance of both specificity and 
induced fit afforded by these domains. Moreover, the structural studies with LBDs provided 
rational guidance for ligand discovery and optimization. Multiple types of synthetic ligands 
were successfully produced for NR LBDs, with these molecules are capable of evoking a 
range of physiological responses ranging from full antagonism to full agonism. Structural 
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biology has provided the field with both the language and visual understanding for how 
DNA, ligand, and coregulator interactions are achieved within the constraints of single 
receptor domains.
At the same time, the intensive use of isolated fragments slowed the field from fully 
appreciating the likelihood and consequences of domain-domain communications. A small 
perturbation such as base-pair difference between two response elements sensed by the 
DBDs, a disease mutation, a PTM, or a switch in ligand type at the LBD, could manifest by 
changing the function elsewhere within NR polypeptides. The two current crystal structures 
of multi-domain complexes of NRs demonstrate distinct and alluring types of domain-
domain interfaces, providing important lessons about the consequences of quaternary 
organization in NR architectures. Given the multitude of macromolecular interactions 
required for NR function in physiological settings, there is still much to be discovered about 
the physical and functional principles that govern signal propagation in these receptors.
In recognizing the importance of domain-domain connections in NR complexes, one can 
begin to consider designing allosteric ligands that don’t just change coregulator affinities at 
the LBD in the way of conventional ligands, but that instead impact DNA affinity, response 
element selectivity, or receptor regulation by PTMs. Many synthetic NR ligands have 
already been discovered using the classic screening strategies that rely on NRs LBDs, but 
rarely have such molecules proven to be selective modulators with gene specific actions. 
Understanding the precise details of allosteric communications and domain-domain 
connections should help enhance success in identifying NR ligands with more desirable and 
specific actions. Indeed, allosteric modulators for other protein classes have been 
discovered, and success in finding allosteric molecules for NRs will be enhanced when 
appropriate screening strategies are employed that fully exploit the structural information 
emerging for full-length NR complexes.
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Figure 1. 
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Domain Organization of NRs and their Interaction Partners. A, NR polypeptides have an N-
terminal domain (NTD) that is variable in size and sequence, a conserved DBD, a variable 
hinge region, and a twelve helical LBD. Several NRs also contain a variable F-domain 
positioned at their C-termini. B, Schematic showing how a dimeric NR uses different 
domains to bind to DNA and ligand. C, NRs can be modulated by ligands that either activate 
or repress gene targets. Repression is mediated by complexes that have corepressors 
(SMRT/N-CoR and histone deacetylases or HDACs), among other components. Activation 
requires the coactivator complexes (p160 family members and histone acetyltransferases or 
HATs). The repressive and activating complexes block or promote transcription. D, 
Oligomeric Complexes of NRs and DNA Response Element Repertoires. Receptors can be 
organized into distinct oligomeric states such as heterodimers with the common partner 
RXR, homodimers, or monomers. The non-steroid receptor heterodimers and many 
homodimers bind to direct repeat response elements with various inter-half-site spacings. 
Steroid receptor homodimers mainly use palindromic DNA elements, where the two half 
sites are in an inverted repeat fashion. Other receptors use monomeric sites extended at their 
5′ end with short sequences used for selectivity. Several examples of receptors falling into 
each of these four categories are shown.
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Figure 2. 
Understanding domain-domain integration in nuclear receptors requires structural studies 
that utilize the complete receptor complexes. A major goal has been to understand allosteric 
communications: how signals in one domain may be efficiently transmitted to a distal 
domain in the quaternary fold (Chandra et al. 2008; Chandra et al. 2013).
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Figure 3. 
The Basis for DNA Recognition. A, The core DBD is the 66 residue region with two zinc 
binding modules. This domain is responsible for the recognition of hexameric DNA half-
sites. Shown on the left is the core DBD structures of RXR(blue) and RAR (red) 
superimposed. The C-terminal extension (CTE) of the DBD, which lies within the 
immediate hinge region, can also participate in DNA binding and spacer recognition. Shown 
on the right is the superposition of the DBD-CTE segments of NGFI-B (green), LRH-1 
(cyan), VDR (yellow), TR (magenta) and Rev-Erb (salmon). While the core DBDs are well 
conserved in fold, the CTE sequences and their structures are divergent. The CTEs can act 
as discriminators of DNA spacing. B, RAR DBD interactions with AGGTCA elements. 
DNA half-site recognition by NRs involves a series of hydrophilic residues positioned on 
the same face of the DBD recognition helix. These residues read the DNA base-pair 
sequence at the major groove. Other basic amino-acids additionally stabilize DNA binding 
by interacting with the phosphate backbone of the DNA. Crystallographic studies have 
shown that water molecules (shown as red or black circles) often help mediate DNA 
contacts.
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Figure 4. 
The Interactions of DBDs with Response Elements. Shown are structures of NR DBD 
homodimers, heterodimers and monomers on response elements consisting of direct repeats 
(DRs), palindromes (Pal) and single half-sites. The spacer size has a dramatic effect on the 
relative rotation and displacement of the two DBDs, fostering their productive dimerization 
contacts on the correctly spaced element, but blocking their dimerization when the spacing 
size is incorrect. Monomeric NRs use the same consensus half-sites, but rely on the 
immediate flanking base-pairs upstream of their half-site for response element 
discrimination.
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Figure 5. 
Structural Properties of NR LBDs. A, The comparison of the unliganded RXRα with the 
liganded RARγ first suggested that ligands can induce multiple changes in the LBD 
conformation, most strikingly in the positioning of helix-12. The movement of helix-12 
(shown in red) allows the ligand binding pocket to become enclosed to prevent ligand 
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escape, in what can be described as a trapping mechanism. Other smaller rearrangements are 
additionally induced by ligand binding (blue arrows). B, Typical dimerization surfaces that 
form between receptor LBDs. Shown here are the LXR-RXR LBD heterodimer and the ER 
LBD homodimer. For two LBDs to dimerize, surfaces from helix-7, helix-9, and helix-10/11 
participate in forming the dimeric interfaces.
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Figure 6. 
Coactivator Binding to the Surface of the LBD. A, Shown is the RORβ LBD structure with 
an agonist ligand (blue) that places helix-12 in the active conformation. From this position, 
helix-12 fosters the interactions of an LXXLL motif contained in most p160 coactivators 
with the surface of the LBD. The LXXLL motif forms a small helical segment, allowing the 
leucines along one face to firmly dig into a hydrophobic groove on the surface of the LBD. 
The X residues in the coactivator motif are typically polar and interact with the solvent. 
Notice that the ligand (blue) is shielded from solvent when helix-12 is in the active 
conformation.
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Figure 7. 
Structural Understanding of how Agonists and Antagonists Mediate their Effects on the 
Estrogen Receptor. A, Estradiol and the synthetic molecule diethylstilbesterol are both 
agonists, whereas tamoxifen and raloxifene are antagonists. The antagonists differ from 
stilbesterol only in the addition of the extension moiety (in blue). B, DES binding places 
helix-12 in the agonist conformation, as does estradiol. C, The extension moiety in 
raloxifene pushes helix-12 out of its active conformation.
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Figure 8. 
Comparison of Coactivator and Corepressor Binding Modes. A, The synthetic ligand 
GW731 is an agonist of PPARα, producing the active conformation and allowing for 
favorable coactivator binding. B, By contrast, the synthetic molecule GW6471 displaces 
helix-12 in this receptor, and helps create a surface conformation that allows for a region of 
the corepressor SMRT to bind onto the surface. C, The binding of the Rev-Erbα LBD to a 
corepressor element in the absence of ligand.
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Figure 9. 
Demonstration of the Distinct Orientations of Cholesterol Derived Ligands in Receptor 
Pockets. A, Shows FXR binding to the bile acid CDCA. B, Shown are the details of 
interactions, with solid red lines indicating hydrogen bonds and dotted lines indicating van 
der Waals interactions. Note that the steroidal A-ring is positioned at helix-12. C–D, LXRα 
binding to epoxycholesterol requires the steroidal A-ring to be in the opposite direction, 
while its side-chain points at helix-12.
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Figure 10. 
The LBD Pockets Can Adapt to Bind Diverse Molecules through Induced-Fit. A, Shown is 
the GR LBD with three distinct compounds. B, The surface volumes of the three ligands 
occupied in the pocket.
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Figure 11. 
Crystal structures of Multi Domain NR complexes. On the left is the PPARγ-RXRα 
complex on DR1, and on the right side is the HNF-4α homodimer on DR1. RXR is blue and 
PPAR is red. The upstream subunit of HNF-4α is yellow and the downstream subunit is 
orange. The green arrows show the direction of the AGGTCA direct repeats in the DR1 
response elements in the lower panel for both complexes. Three views of each complex are 
shown.
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